Argenx
ARGX
#419
Rank
HK$436.61 B
Marketcap
HK$7,011
Share price
-1.62%
Change (1 day)
47.49%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2025 (TTM): HK$7.50 Billion

According to Argenx 's latest financial reports the company's current earnings are HK$3.60 Billion. In 2024 the company made an earning of HK$0.66 Billion, an increase over its 2023 earnings that were of -HK$2.37 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) HK$7.50 B1032.09%
2024 HK$0.66 B-127.97%
2023 -HK$2.37 Billion-58.25%
2022 -HK$5.68 Billion
2019 -HK$1.55 Billion124.86%
2018 -HK$0.69 Billion131.81%
2017 -HK$0.3 Billion54.9%
2016 -HK$0.2 Billion33.71%
2015 -HK$0.15 Billion12.93%
2014 -HK$0.13 Billion46.39%
2013 -HK$86.68 Million